City provides $450,000 SBIR / STTR matching grants to support life sciences commercialization in Philadelphia

Great news! The Philadelphia Department of Commerce, Office of Business Development has awarded $450,000 in SBIR/STTR Matching Grants to 21 life sciences companies, marking Pennsylvania's first City-led matching grant program of its kind. These awards support life sciences companies that received Phase 1 or Phase 2 of the Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) grants from the federal government in 2022 or later. These funds are to be used exclusively for technical and business assistance activities that support the commercialization of each life sciences companies' SBIR/STTR research.

The University City Science Center serves as the City's implementation partner and will work directly with each awardee to deploy funds in alignment with their commercialization goals. This approach helps ensure that support is tailored to each company's needs and focused on accelerating their progress toward real-world application.

Philadelphia awardees

The life sciences companies that received SBIR / STTR matching grants from the Department of Commerce are:

• AlphaThera, Inc.
• Axonova Medical
• BioLattice Ophthalmics, Inc.
• BriaCell Therapeutics Corp.
• Goeppert LLC
• HeyKiddo, LLC
• Linnaeus Therapeutics, Inc.
• Flik Therapeutics, Inc.
• FluidiSpec, LLC
• Phrase Health, Inc.
• Mechano Therapeutics
• RTM Vital Signs, LLC
• Serentrix, LLC
• Integral Molecular, Inc.
• Instadiagnostics, Inc.
• Vetigenics, Inc.
• Trevarx Biomedical, Inc.
• Recupero Robotics, LLC
• Vasowatch Inc
• Vellum Biosciences, LLC
• Young Therapeutics, LLC

Questions? Email [email protected].

Philadelphia's life sciences and biotechnology sector continues to be a driver of innovation and economic growth. These companies are advancing therapeutic discoveries, developing new technologies, and creating skills-based job opportunities for Philadelphians.

These awards from the Department of Commerce represent a meaningful step forward for Philadelphia's innovation economy by supporting local companies while laying the groundwork for long-term growth, scientific advancement, and improved outcomes for patients.